[{"orgOrder":0,"company":"Qiagen","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qiagen \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Qiagen \/ Amgen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS protein","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AMG 510","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Amgen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Qiagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qiagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Qiagen \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Carmot Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Carmot Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Labcorp \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Labcorp \/ Amgen"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NYU Grossman School of Medicine \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"NYU Grossman School of Medicine \/ Amgen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Amgen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAR442720","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Vociprotafib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Sanofi"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VITRAC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for AMG510
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
